1. Yu E, Sharma S. 2020. Cystic fibrosis. Statpearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2020, StatPearls Publishing LLC.
2. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, Hiatt P, McCoy K, Wilson CB, Inglis A et al. 2001. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 32(5):356-366.
3. Zolin A OA, Naehrlich L, Jung A, van Rens J et al. 2020. Ecfspr annual report 2018.
4. Cystic fibrosis foundation patient registry, 2018 annual data report, bethesda, maryland.
5. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. 2002. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 34(2):91-100.
6. Vanderhelst E, De Meirleir L, Verbanck S, Piérard D, Vincken W, Malfroot A. 2012. Prevalence and impact on fev1 decline of chronic methicillin-resistant staphylococcus aureus (mrsa) colonization in patients with cystic fibrosis: A single-center, case control study of 165 patients. Journal of Cystic Fibrosis. 11(1):2-7.
7. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. 2010. Association between respiratory tract methicillin-resistant staphylococcus aureus and survival in cystic fibrosis. JAMA. 303(23):2386-2392.
8. Cystic fibrosis trust. Recommendations – eradication and treatment of mrsa. In: Antibiotic treatment for cystic
fibrosis. 3rd edn. Bromley, cystic fibrosis trust, 2009.
9. Mogayzel PJ, Jr., Naureckas ET, Robinson KA, Brady C, Guill M, Lahiri T, Lubsch L, Matsui J, Oermann CM, Ratjen F et al. 2014. Cystic fibrosis foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial pseudomonas aeruginosa infection. Ann Am Thorac Soc. 11(10):1640-1650.
10. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA. 2014. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc. 11(7):1120-1129.
11. Taccetti G, Bianchini E, Cariani L, Buzzetti R, Costantini D, Trevisan F, Zavataro L, Campana S, Italian Group for PaEiCF. 2012. Early antibiotic treatment for pseudomonas aeruginosa eradication in patients with cystic fibrosis: A randomised multicentre study comparing two different protocols. Thorax. 67(10):853-859.
12. Döring G, Flume P, Heijerman H, Elborn JS. 2012. Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. J Cyst Fibros. 11(6):461-479.
13. Palser S, Smith S, Nash EF, Agarwal A, Smyth AR. 2019. Treatments for preventing recurrence of infection with pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 12:CD012300.
14. Langton Hewer SC, Smyth AR. 2017. Antibiotic strategies for eradicating pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews. (4).
15. Lo DK, Muhlebach MS, Smyth AR. 2018. Interventions for the eradication of meticillin-resistant staphylococcus aureus (mrsa) in people with cystic fibrosis. Cochrane Database Syst Rev. 7:CD009650.
16. Hewer SCL, Smyth AR, Brown M, Jones AP, Hickey H, Kenna D, Ashby D, Thompson A, Williamson PR. 2020. Intravenous versus oral antibiotics for eradication of pseudomonas aeruginosa in cystic fibrosis (torpedo-cf): A randomised controlled trial. Lancet Respir Med. 8(10):975-986.
17. Yohannes AM, Willgoss TG, Fatoye FA, Dip MD, Webb K. 2012. Relationship between anxiety, depression, and quality of life in adult patients with cystic fibrosis. Respir Care. 57(4):550-556.
18. Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M et al. 2017. Diagnosis of cystic fibrosis: Consensus guidelines from the cystic fibrosis foundation. The Journal of Pediatrics. 181:S4-S15.e11.
19. Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM. 2003. Evaluation of a new definition for chronic pseudomonas aeruginosa infection in cystic fibrosis patients. Journal of Cystic Fibrosis. 2(1):29-34.
20. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ. 2000. Antibiotic therapy against pseudomonas aeruginosa in cystic fibrosis: A european consensus. Eur Respir J. 16(4):749-767.
21. Vandekerckhove K, Keyzer M, Cornette J, Coomans I, Pyl F, De Baets F, Schelstraete P, Haerynck F, De Wolf D, Van Daele S et al. 2017. Exercise performance and quality of life in children with cystic fibrosis and mildly impaired lung function: Relation with antibiotic treatments and hospitalization. Eur J Pediatr. 176(12):1689-1696.
22. Akil N, Muhlebach MS. 2018. Biology and management of methicillin resistant staphylococcus aureus in cystic fibrosis. Pediatr Pulmonol. 53(S3):S64-S74.
23. Noah TL, Ivins SS, Abode KA, Stewart PW, Michelson PH, Harris WT, Henry MM, Leigh MW. 2010. Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and pseudomonas. Pediatr Pulmonol. 45(3):281-290.
24. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T et al. 2011. Comparative efficacy and safety of 4 randomized regimens to treat early pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Pediatrics & Adolescent Medicine. 165(9):847-856.
25. Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De Boeck K. 2013. Comparison of two treatment regimens for eradication of pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros. 12(1):29-34.
26. Poster session abstracts. 2016. Pediatric Pulmonology. 51(S45):S194-S485.
27. Belarski E, Pettit R. 2020. Outcomes of a methicillin-resistant staphylococcus aureus (mrsa) eradication protocol in pediatric cystic fibrosis (cf) patients. Pediatr Pulmonol. 55(3):654-659.
28. Doe SJ, McSorley A, Isalska B, Kearns AM, Bright-Thomas R, Brennan AL, Webb AK, Jones AM. 2010. Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros. 9(2):104-109.
29. Dolce D, Neri S, Grisotto L, Campana S, Ravenni N, Miselli F, Camera E, Zavataro L, Braggion C, Fiscarelli EV et al. 2019. Methicillin-resistant staphylococcus aureus eradication in cystic fibrosis patients: A randomized multicenter study. PLOS ONE. 14(3):e0213497.
30. Kappler M, Nagel F, Feilcke M, Kroner C, Pawlita I, Naehrig S, Ripper J, Hengst M, von Both U, Forstner M et al. 2016. Eradication of methicillin resistant staphylococcus aureus detected for the first time in cystic fibrosis: A single center observational study. Pediatr Pulmonol. 51(10):1010-1019.
31. Vallieres E, Rendall JC, Moore JE, McCaughan J, Hoeritzauer AI, Tunney MM, Elborn JS, Downey DG. 2016. Mrsa eradication of newly acquired lower respiratory tract infection in cystic fibrosis. ERJ Open Res. 2(1).
32. Jackson L, Waters V. 2021. Factors influencing the acquisition and eradication of early <em>pseudomonas aeruginosa</em> infection in cystic fibrosis. Journal of Cystic Fibrosis. 20(1):8-16.
33. Rosenfeld M, Emerson J, McNamara S, Thompson V, Ramsey BW, Morgan W, Gibson RL. 2012. Risk factors for age at initial <em>pseudomonas</em> acquisition in the cystic fibrosis epic observational cohort. Journal of Cystic Fibrosis. 11(5):446-453.
34. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. 2008. Persistent methicillin-resistant staphylococcus aureus and rate of fev1 decline in cystic fibrosis. Am J Respir Crit Care Med. 178(8):814-821.
35. Jennings MT, Dasenbrook EC, Lechtzin N, Boyle MP, Merlo CA. 2017. Risk factors for persistent methicillin-resistant staphylococcus aureus infection in cystic fibrosis. J Cyst Fibros. 16(6):681-686.